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Intravenous (IV) iron therapy is widely used in iron deﬁciency anaemias when oral iron is not tolerated or ineffective.
Administration of IV-iron is considered a safe procedure, but severe hypersensitivity reactions (HSRs) can occur at a very low fre-
quency. Recently, new guidelines have been published by the European Medicines Agency with the intention of making IV-iron
therapy safer; however, the current protocols are still non-speciﬁc, non-evidence-based empirical measures which neglect the fact
that the majority of IV-iron reactions are not IgE-mediated anaphylactic reactions. The ﬁeld would beneﬁt from new speciﬁc and
effectivemethods for the prevention and treatment of these HSRs, and themain goal of this reviewwas to highlight a possible new
approach based on the assumption that IV-iron reactions represent complement activation-related pseudo-allergy (CARPA), at
least in part. The review compares the features of IV-iron reactions to those of immune and non-immune HSRs caused by a variety
of other infused drugs and thus make indirect inferences on IV-iron reactions. The process of comparison highlights many unre-
solved issues in allergy research, such as the unsettled terminology, multiple redundant classiﬁcations and a lack of validated
animal models and lege artis clinical studies. Facts and arguments are listed in support of the involvement of CARPA in IV-iron
reactions, and the review addresses themechanism of low reactogenic administration protocols (LRPs) based on slow infusion. It is
suggested that consideration of CARPA and the use of LRPs might lead to useful new additions to the management of high-risk
IV-iron patients.
Abbreviations
ADRs, adverse drug reactions; API, active pharmaceutical ingredient; CARPA, complement activation-related pseudo-
allergy; CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicinal Agency; HMW-ID, high
molecular weight iron dextran; HSRs, hypersensitivity reactions; ID, intravenous dextran; IV-iron, intravenous iron;
LMW-ID, low molecular weight iron dextran; LRP, low reactogenic administration protocol; Mab, monoclonal antibody;
MBL, mannose binding lectin; MRI, magnetic resonance imaging; SPIO, superparamagnetic iron oxide; WAO, World
Allergy Organisation
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Introduction
Roughly 25% of all adverse drug reactions (ADRs) are hyper-
sensitivity reactions (HSRs), affecting up to some half-million
patients in the USA every year (Lazarou et al., 1998). Such
reactions can be caused by almost all types of drugs, irrespec-
tive of their chemical composition, complexity or route of
administration. Because of recent public concern about the
HSRs caused by one of such reactogenic drugs, namely
intravenous iron (IV-iron) compounds (European Medicines
Agency– Committee for Medicinal Products for Human Use
(EMA-CHMP), 2013), this review focuses on the HSRs caused
by these preparations.
Parenteral iron (IV-iron) has become an important
treatment for iron deﬁciency anaemia in a wide range of
therapeutic areas, when oral iron is inappropriate, ineffective
or not tolerated. A recent safety review performed by the
EMA-CHMP concluded that all available IV-iron preparations
on the European market have a positive risk-beneﬁt ratio
and low risk of causing HSRs. Nevertheless, in order to
minimize the risk of life-threatening reactions, new recom-
mendations were introduced for all health care profes-
sionals who provide treatment with IV-iron. The document
(EMA-CHMP, 2013) calls for changes in the practice of IV-iron
infusions (Table 1) and for uniform reporting of HSRs (Ring
and Messmer, 1977; Ring et al., 2010).
However, the ﬁeld would also beneﬁt from scientiﬁc
evidence-based introduction of more speciﬁc and effective
measures than the currently applied common empirical treat-
ments. To achieve this, the mechanisms of IV-iron reactions
should be better understood, and this challenge represents
the main thrust of the present review. Our approach is to
highlight the similarities and differences among iron-
induced and other IV drug-induced HSRs that might give
clues regarding the mechanisms and hence make possible
new methods of prevention and treatment of reactions to
IV-iron. The comparison focuses on the symptoms of reac-
tions categorized by their various properties. The process of
comparison entails addressing some critical unsolved issues
in the ﬁeld, such as the incoherent terminology and lack of
credible clinical data. A summary of current premedication
and treatment options alludes to the inappropriateness of
using antihistamines, because they mimic some of the fea-
tures of HSRs, and provides rationale for the testing of low
reactogenic administration protocols (LRPs), such as low-
dose slow priming followed by slow dose escalation. One par-
ticular new perspective outlined for the ﬁrst time in this re-
view is the possible causal role of complement activation in
IV-iron reactions, a proposal which has both conceptual and
therapeutic implications.
Tables of Links
TARGETS
GPCRs
ATR, anaphylatoxin receptor
C3aR
C5aR
LIGANDS
C3a
C5a
Doxorubicin
Paracetamol (acetaminophen)
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014)
and are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013).
Table 1
New recommendations by the EMA Committee for Medicinal Prod-
ucts for Human Use (CHMP) to manage risk of allergic reactions with
IV-iron (EMA-CHMP, 2013)
1. All prescribers should inform patients of the risk and
seriousness of a hypersensitivity reaction and the
importance of seeking medical attention if a reaction occurs.
2. Patients need to be closely observed for any allergic
reactions during and for at least 30min after IV-iron
injection.
3. IV-iron preparations should only be administered
A. by staff trained to evaluate and manage anaphylactic
and anaphylactoid reactions,
B. in an environment where resuscitation facilities are
available so that the patient can be treated immediately.
4. The current practice of ﬁrst giving the patient a small test
dose is not a reliable way to predict how the patient will
respond when the full dose is given. A test dose is therefore
no longer recommended, but instead, caution is warranted
with every dose of IV-iron that is given, even if previous
administrations have been well tolerated.
5. In case of hypersensitivity reactions, healthcare
professionals should immediately stop the iron
administration and consider appropriate treatment for
the hypersensitivity reaction.
6. IV-iron medicines should not be used during pregnancy
unless clearly necessary. Treatment should be conﬁned to the
second or third trimester, provided the beneﬁts of treatment
outweigh the risk to the unborn baby.
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Features of HSRs to IV-iron compared with
those to other IV drugs
Figure 1 lists the symptoms and various features of HSRs
caused by IV drugs, including IV-iron, by which the symp-
toms have been categorized: organ systems affected, severity,
kinetics, prevalence, duration, mechanism and tolerance in-
duction. Changes of the variables in these categories depend
on the reactogenicity of the drugs involved, the method of
their administration and the patient’s sensitivity. A closer
analysis of these variables reveals both similarities and major
differences between the symptoms of reactions to IV-iron and
to other IV drugs, as detailed below.
The symptoms and their organ expression do not seem to dif-
fer between IV-iron and other drugs, at least on the basis that
almost all listed symptoms and all mentioned organ systems
have been cited for HSRs to both IV-iron and non-iron drugs.
Nevertheless, because the active pharmaceutical ingredients
usually have an effect on the physicochemical features of
the drug and hence on its immune reactivity, it is not impos-
sible that a head-to-head comparison would reveal speciﬁc
effects of iron on HSR symptoms. At this time, however, we
are not aware of such quantitative data in the literature.
For the description of the severity of symptoms, the best
known classiﬁcation of HSRs was described by Ring and
Messmer (Ring and Messmer, 1977; Ring et al., 2010), who
graded the symptoms in categories I–IV. This classiﬁcation,
which should not be confused with Gell and Coombs’ types
I–IV HSRs, which was recommended by the EMA (EMA,
2012) for ADR reporting, despite the existence of a simpler
(Brown, 2004) and amore recent symptom-based grading sys-
tems (Mayer and Young, 2006). Irrespective of how HSRs are
quantiﬁed, from mild to severe, life-threatening reactions
can occur with either IV-iron formulation or other IV drugs.
Severity does not differentiate between iron and non-iron
reactions. Likewise, iron and non-iron HSRs can be acute,
short, delayed and extended. Thus, the kinetics and duration
of symptoms do not provide distinguishing features.
Prevalence is the feature of HSRs that does radically differ
between reactogenic drugs. When expressed as the
percentage of patients displaying HSRs among all those
treated, the range spans 5 orders of magnitude (0.001–70%).
To enable the comparison of prevalence statistics within such
wide limits, we propose clustering the % values into ﬁve
groups (very high, high, moderate, low and very low) with
numerical ranges coinciding with the orders of magnitude
in the 103–102 range (third column in Figure 2).
Table 2 categorizes the main drug types according to HSR
prevalence. It turns out from the compilation that the
highest rate of HSRs occur with certain monoclonal antibod-
ies (mAbs), liposomal drugs and anticancer agents (taxanes),
Figure 1
Hypersensitivity reaction parameters and their different classiﬁcations.
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which are delivered in micellar solvents, such as Cremophor
EL. The frequency of HSRs to penicillin, the textbook
example of drug-induced allergic reactions, falls at the
moderate/high borderline (1%). On the other hand, the prev-
alence of HSRs to different IV-iron preparations is very low, a
feature shared only with the safest radiocontrast agents
(Table 2). In fact, the vast majority of IV-iron administrations
in clinical practice occur with no or minor adverse events.
The heightened public and regulatory concern about these
reactions may therefore be considered to be controversial.
Despite the very low prevalence of IV-iron reactions,
minor but signiﬁcant differences between the risk rates might
have major clinical implications. Analyses of commercial and
public databases (e.g. post-marketing surveillance data and
voluntary submission of ADR reports) have led some authors
to claim differences in the safety proﬁles of currently
available IV-iron products (Chertow et al., 2004; Bailie et al.,
2005; Chertow et al., 2006; Bailie et al., 2011; Bailie, 2012;
Bailie and Verhoef, 2012). These reports were recently
challenged by the EMA document (EMA-CHMP, 2013) and a
recent review by Bircher and Auerbach (Bircher and
Auerbach, 2014) that concluded that insufﬁcient reliable data
are available to support this conclusion. There are many rea-
sons for this uncertainty, such as the confusing terminology
and classiﬁcation of HSRs, under-reporting or differential
reporting of IV-iron reactions, absence of brand names and a
lack of accurate or uniform denominator information
(i.e. whether the HSR rate is given per infusion, per patient,
per time or per all ADRs) (Wysowski et al., 2010). Moreover, ran-
domized clinical trials are not powered to compare very rare
clinical events (Black, 1996). Critchly and Dunbar (2007)
concluded that a study to compare the adverse event rate for
two IV-iron compounds would need about 6600 patients to
achieve the necessary statistical power. Nonetheless, a relatively
higher rate and generally more severe HSRs were observed with
high molecular weight iron-dextran compared with the low
molecular weight formulation (Fletes et al., 2001; Chertow
et al., 2004). Since that time, both high molecular weight-
dextrans (Imferon® and Dexferrum®) have been removed
from the market by the marketing authorisation holders in
USA. The problems with the terminology and classiﬁcation of
HSRs will be discussed in more detail later.
Mechanisms of HSRs to IV-iron versus those to
other IV drugs
The mechanisms of HSRs are categorized in many different
ways, four of which are shown in Figure 1. The oldest and best
known is the classical scheme of Gell and Coombs, which
distinguishes four types of HSRs, Types I–IV (Coombs and
Gell, 1968). The system is based on pathophysiological
principles and has been criticized (Descotes and Choquet-
Kastylevsky, 2001; Rajan, 2003) on the basis that the
adverse immune effects of drugs occur mostly via complex
mechanisms, which cannot be cleanly ﬁtted into Gell and
Coomb’s categories. One important example is direct
complement activation causing type I reactions, because
these reactions are deﬁned by Gell and Coombs as being
solely IgE-mediated.
Figure 2
Scheme illustrating the anaphylatoxin concept of HSRs. Iron and other nanoparticles activate the complement system (upper red arrow) that leads
to the formation of anaphylatoxins. Their blood level is determined by generation via this activation process, and by consumption, due partly to
cellular uptake and partly to metabolism by carboxypeptidases (green). The level in blood determines whether or not anaphylatoxins trigger mast
cells for release reaction (lower red arrow). A scheme of complement activation (left insert) and the main vasoactive mediators released frommast
cells are also shown.
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Among the alternative classiﬁcations of HSRmechanisms,
Descotes proposed three categories: immunoglobulin-
mediated, cell-mediated and pseudoallergic (Descotes and
Choquet-Kastylevsky, 2001). Pichler labelled his ﬁve catego-
ries with Greek letters: α-type reactions involve cytokine
release, β-type reactions are immune reactions against
biological agents, γ-type reactions are immune or cytokine
imbalance syndromes, δ-type reactions arise because of
cross-reactivity, and ε-type reactions do not directly involve
the immune system (Pichler, 2006). The last mechanistic
scheme was proposed by one of us (Szebeni, 2005), in which
the Gell and Coombs’ type I reactions were subdivided ac-
cording to the mechanism of mast cell (and basophil) activa-
tion. The scheme suggests a distinction between direct and
receptor-mediated stimulation of mast cells and basophils,
with the latter arm subdivided to (1) FcεR, (2) anaphylatoxin
receptor (ATR, C5aR and C3aR) and (3) both FcεR and
ATR-mediated mixed responses. The IgE-R-mediated HSRs
are the classical type I reactions, while the ATR-mediated re-
lease reactions underlie complement activation-related
pseudoallergy (CARPA) (Szebeni, 2005), which can occur
without the presence of any speciﬁc antibodies or immune
competent cells.
As for mechanistic distinction between IV-iron reactions
and other IV-drug-induced reactions, the weight of evidence
suggests that IV-iron reactions are not IgE-mediated (Fleming
et al., 1992; Novey et al., 1994). However, other than this con-
clusion, there is insufﬁcient information to prove any other
Table 2
Frequency of HSRsa in patients treated IV with different reactogenic drugs
Reaction rate Drugs Drug Type
Very high P> 10% Rituximab, inﬂiximab mAb
Doxil (Caelyx), AmB (AmBisome) Liposome-encapsulated
Taxanes (paclitaxel, docetaxel), platinum Micellarized anticancer
High 1%< P <10% Natalizumab, cetuximab, trastuzumab, panitumumab,
gentuzumab
mAb
Amphotec, Myocet, Amphocyl, DaunoXome, Abelcet,
Visudyne
Liposome
Penicillin Antibiotic
Platinum compounds (cisplatin, carboplatin), Anticancer drugs
Moderate 0.1< P % <1 Omalizumab Monoclonal antibodies (mAbs)
Alemtuzumab
Trastuzumab
Cephalosporins/carbapenems, aztreonam, imipenem Antibiotics
Iodinated contrast agents (Ioxaglate, Iohexol,
Iopamidol, Ioversol, Iopromide, Ioxilan)
Radiocontrast agents
low 0.01< P % <0.1 Bevacizumab mAb
Epipodophyllotoxins (teniposide, etoposide),
asparaginase, procarbazine, doxorubicin,
6-mercaptopurine
Anticancer drugs
Acetaminophen (paracetamol), aspirin, ibuprofen Anaesthetics, analgesics antalgics,
antipyretics and non-steroidal
anti-inﬂammatory drugs
Phenytoin, carbamazepine phenobarbital sodium
Lamotrigine, primidone diphenylhydantoin,
sulfonamides (procainamide), sulfonylureas
Anticonvulsants (antiepileptics)
Iodinated contrast agents (ioxaglate, iohexol, iopamidol,
ioversol, iopromide, ioxilan, iodixanol, Gd-GTPA
Contrast agents
Venofer, Cosmofer, Ferinject, Monofer, Ferrlecit,
Ferumoxytol
IV-ironb
Very low P< 0.01 SonoVue Contrast agents
Venofer, Cosmofer, Ferinject, Monofer, Ferrlecit,
Ferumoxytol
IV-ironb
aAll types of reactions regardless of severity. Rates were obtained from individual box labels, public (internet) information or Summaries of Product
Characteristics.
bData uncertain to select the exact category, P = prevalence.
Hypersensitivity reactions to intravenous iron BJP
British Journal of Pharmacology (2015) 172 5025–5036 5029
‘immune’ mechanism. Among the non-immune mechanisms,
there are several lines of indirect evidence suggesting that
CARPAmayplay a causal role in IV-iron reactions. This hypothesis
will be described in substantial detail later in this review.
Risk factors of HSRs to IV-iron versus other IV
drugs
The risk factors for IV-iron reactions include genetic predispo-
sition, general nonspeciﬁc factors and unique temporary
conditions. Among the genetic predispositions, atopic con-
stitution is the best recognized, in which the patients have
an innate proneness for asthma or allergy to drugs, pollens
and other allergens (Enright et al., 1989; Goss et al., 1995;
Brannagan, 2002; Laman et al., 2005; Hong et al., 2012;
Kelsall et al., 2012; Auerbach et al., 1998, 2011; Fletes et al.,
2001; Fishbane, 2003). The acquired lasting risk factors in-
clude, among others, old age, concurrent or past cardiovascu-
lar disease, autoimmune diseases and mastocytosis (Ansell
et al., 1980; Shehadi, 1982; Goss et al., 1995; Simons et al.,
2011), while the acquired temporary risk factors are exempli-
ﬁed by infectious diseases, certain medications [e.g.
β-adrenoceptor blockers, ACE inhibitors (Goss et al., 1995;
Simons et al., 2011) and even psychological distress (Lalli,
1974; Misbah and Chapel, 1993]. We are not aware of signiﬁ-
cant differences between IV-iron and other IV drugs in rela-
tion to the risk factors mentioned above.
Unsolved issues in clinical research on HSRs to
IV-iron and other IV drugs
As pointed out by Auerbach et al., there is an unmet medical
need for a uniform and commonly accepted deﬁnition of ad-
verse events to iron compounds, the absence of which at pres-
ent is a major reason for the statement that ‘reliable
comparative safety data do not exist’ (Auerbach and Ballard,
2010). In fact, one major problem in clinical HSR research is
its complex and sometimes confusing terminology.
There is a long list of different descriptive, qualitative and
quantitative terms for essentially the same acute illness
(abnormal immune stimulation), leading the World Allergy
Organization to a Nomenclature Review conference in 2004
(Johansson et al., 2004). Subsequently, the list of terms has
expanded (Table 3), among which the use of ‘immunological’
and ‘non-immunological’ HSRs to differentiate between
IgE-mediated reactions from all others is particularly ques-
tionable, because the involvement of IgE or other speciﬁc
antibodies in HSRs often cannot be proved or has not even
been tested (Johansson et al., 2004; Kemp et al., 2008). This
problem applies to all HSRs, including IV-iron reactions.
In addition to the ambiguous terminology, anaphylaxis
research is hindered by two other factors: (1) the rarity of
severe reactions, making it difﬁcult, if not impossible, to set
up comparative trials according to the principles of
evidence-based medicine, and (2) the lack of animal models,
which mimic the symptoms of human HSRs. As for the ﬁrst
Table 3
Terms used for different hypersensitivity reactions
Term Type Deﬁnition Mechanism Severity
Drug allergy Descriptive Hypersensitivity to drugs Any Mild-to-severe
Infusion reaction Descriptive HSR arising as a consequence
of infusion
Any Mild-to-severe
Idiosyncratic reaction Descriptive HSR without known reason Any Mild-to-severe
Anaphylaxis Quantitative Severe, life-threatening generalized
or systemic HSR
Any Severe
Pseudoallergy Qualitative Systemic and/or local signs of HSR Any mechanism with
no role speciﬁc IgE
Mild-to-severe
Non-allergic
hypersensitivity
Qualitative Systemic and/or local signs of HSR Any mechanism with
no role speciﬁc IgE
Mild-to-severe
Non-immune
hypersensitivity
Qualitative Systemic and/or local signs of HSR Any mechanism with
no role speciﬁc IgE
Mild-to-severe
Complement-activation-
related pseudoallergy
(CARPA)
Qualitative Systemic and/or local signs of HSR Complement activation is
involved directly or indirectly
Mild-to-severe
Immunological
anaphylaxis
Qualitative and
quantitative
mediated by speciﬁc IgE Severe
Non-immunological
anaphylaxis
Qualitative and
quantitative
Not mediated by speciﬁc IgE Severe
Anaphylactoid reaction Qualitative and
quantitative
Not mediated by speciﬁc IgE Mild-to-severe
Type B adverse drug
reaction
Qualitative and
quantitative
Drug dose-independent systemic
and/or local signs of HSRa
Any Severe
aScott and Thompson (2014).
BJP J Szebeni et al.
5030 British Journal of Pharmacology (2015) 172 5025–5036
problem, instead of Phase I toxicity/safety-evaluation
followed by randomized, placebo-controlled clinical trials,
clinical evidence in the ﬁeld of anaphylaxis is mostly based
on retrospective analyses of large databases and medical
records, which can seldom answer speciﬁc, prospective ques-
tions regarding safety or efﬁcacy.
The problem of animal models of anaphylaxis lies in
their divergence from humans in their sensitivity to differ-
ent reactogenic drugs, and in the frequency of occurrence
and symptoms of reactions. For these reasons there is no
validated animal model of human HSRs provoked either
by drugs, or other causes, for example foods, insect stings,
surgery and exercise. Nevertheless, animal models are use-
ful for the study of some common steps in anaphylaxis at
the cellular and subcellular level, for example mast cell
degranulation (Nauta et al., 2008).
One aspect of progress in this ﬁeld that awaits profes-
sional and regulatory recognition is the use of pig models of
CARPA, because pigs, unlike rats and mice, resemble humans
in their haemodynamical, haematological, biochemical and
skin responses to many nanomedicines (liposomes, micellar
drugs, radiocontrast agents, polymers, antibodies, protein
drugs and enzymes) with unique sensitivity and reproducibil-
ity (Szebeni et al., 1999b; 2000; 2006; 2007; 2012a, 2012b,
2012c; Szebeni, 2014; Merkel et al., 2011; Dézsi et al., 2014).
It is this model that presents both tachyphylactic and non-
tachyphylactic reactions and therefore allows prediction of
the efﬁcacy of slow infusion and prophylactic desensitization
with drug carriers (such as empty liposomes) (Szebeni et al.,
1999a, 2011, 2012a, 2012b, 2012c; Dézsi et al., 2014).
Whether IV-iron nanoparticles will trigger CARPA in pigs
awaits experimental exploration.
Current prevention and treatment of HSRs to
IV-iron and other IV drugs
The prevention and treatment options for HSRs to IV-iron and
other IV drugs differ according to the severity and prevalence
of HSRs. For reaction prevention, there are two options:
premedication and the use of LRPs.
The premedication regimes usually include corticoste-
roids and antihistamines, along with a variety of additional
agents, including paracetamol (acetaminophen). However,
the efﬁcacy of premedication to prevent mild and moderate
HSRs has been queried, and many authors believe that
premedication for all patients are not justiﬁed and that
premedication should be reserved only for patients at in-
creased risk (Tramer et al., 2006). Among other causes of scep-
ticism, the beneﬁt of antihistamines has been questioned on
the basis that they increase the frequency of ADRs (Lorenz
and Doenicke, 1985; Baller and Huchzermeyer, 1989;
Wasserman et al., 2004) and that the symptoms they produce
can mimic those of a mild HSR (Auerbach and Ballard, 2010).
Paracetamol is as effective alone as it is given together with
antihistamines (Keshavarzian et al., 2007). Taking this evi-
dence together, we conclude that there is now no place for
the use of antihistamines for the prevention or treatment of
HSRs to IV-iron.
The use of LRPs is the other potential safety measure to
prevent HSRs to IV drugs. Two groups of IV medicines were
shown to beneﬁt most from this approach: therapeutic mAbs
and liposomal drugs. LRP for mAbs was introduced by
Puchner et al. (Puchner et al., 2001) to prevent HSRs to
inﬂiximab. Their protocol involved an 11-step progressive
dose escalation over 4 h, a technique which was later applied
for other antineoplastic mAbs including rituximab,
cetuximab and trastuzumab (Duburque et al., 2006; Castells,
2008; Castells et al., 2008; Brennan et al., 2009). The infusion
rates and timing of escalation steps were different in the var-
ious protocols, and they were often combined with anti-
allergic pre-medications. What is common to all LRPs is that
the infusion is started at a very low rate carrying 0.001 to
0.01% of the full drug dose in 5–15min. This priming may
serve two functions: (1) desensitization of the patient to the
drug and (2) alarming for the presence of hypersensitivity.
The use of LRP to prevent liposome reactions was ﬁrst ap-
plied for the infusion of doxorubicin-HCl liposomes (Doxil);
Gabizon and Muggia, 1998). The liposome infusion was
initially administered at a rate of 1mg doxorubicin min1,
and if no reactions occurred, the rate was increased to
complete the IV therapy over 1 h. This method remains the
recommended protocol for Doxil administration today
(Doxil prescribing information, 2014).
LRP has also been applied successfully for the prevention
of IV-iron reaction in high-risk patients, with a history of life-
threatening reactions (Altman and Petersen, 1988; Monaghan
et al., 1994; Hickman et al., 2000). However, because HSRs to
IV-iron occur at a low, or very low rate, such an approach may
not be needed in the average, risk factor-free patient.
The treatment options forHSRs to IVdrugs and iron, because
they are therapeutic rather than preventive, are also referred to
as ‘reactive’ (Lequerre et al., 2006; Mayer and Young, 2006).
As summarized in Table 4, these options also depend on
the severity of reactions and are identical regardless of the
cause of HSR.
The treatment of very severe reactions, that is anaphy-
laxis, is special in that these events are very rare, and themed-
ications applied are rarely ‘evidence-based’. As stated earlier,
it is impracticable to perform randomized controlled trials
on clinical conditions that are very rare (Black, 1996), a con-
clusion which also applies to clinical investigations into the
most effective treatment of severe anaphylaxis (Ring et al.,
2010; Working Group of the Resuscitation Council, UK,
2013). In this context, Ranft and Kochs (2004) concluded
that ‘None of the traditionally applied remedies against ana-
phylaxis – epinephrine and intravascular volume replace-
ment, histamine receptor blockade, inhaled beta-mimetics
and steroids – have been proved efﬁcacious by means of
evidence-based medicine – there is a lack of consensus as to
the substantial elements of therapy’. Despite the methodo-
logical challenges, Ring et al. (2010) concluded that
‘Adrenaline (epinephrine) is the essential anti-anaphylactic
drug. Glucocorticoids are given in order to prevent a
protracted or biphasic course of anaphylaxis; they are of
little help in the acute treatment. H1 antagonists are
valuable in mild anaphylactic reactions; they should be
given intravenously if possible. The replacement of volume
is crucial in anti-anaphylactic treatment’. These recommen-
dations are largely in agreement with most major guide-
lines for the treatment of life-threatening anaphylaxis
(Simons et al., 2011; Working Group of the Resuscitation
Committee, 2013).
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The anaphylatoxin concept of HSRs to IV-iron
and efficacy of LRPs
Perhaps the most important conclusion from the comparison
of HSRs to IV-iron and other IV drugs is that, other than
prevalence, there are no major qualitative or quantitative
differences between these reactions. Considering that the
overwhelming majority (77%) of all HSRs are not IgE-
mediated (Demoly et al., 1999), it seems reasonable to assume
that IV-iron reactions could have the same ‘non-immune’
underlying mechanism as the majority of other IV-drugs.
One of the non-immune mechanisms that have received
much attention recently is CARPA, which has been claimed
to be a common cause for, or contributing factor to all acute
HSRs provoked by any infusion that contains complement-
activating antibodies or nanoparticles.
That complement activation plays a causal role in the
HSRs to rituximab, was shown by van der Kolk et al. (van
der Kolk et al., 2001), while for liposomal preparations,
including Doxil, several lines of evidence have accumulated
over the past two decades (Szebeni J et al. 1994–2014). For ex-
ample, a clinical investigation showed that strong comple-
ment activation in patients with cancer infused with Doxil
correlated with the severity and frequency of HSRs and that
the rate of drug infusion was critical both in the risk of HSR
and complement activation (Chanan-Khan et al., 2003). The
study could even accurately predict the upper threshold of safe
initial infusion rate (0.38mg doxorubicin min1) on the basis
of a signiﬁcant correlation between initial infusion rate and
in vivo production of SC5b-9, an index of complement activa-
tion. Such measurements and calculations may be useful for
the development of LRPs for other reactogenic drugs.
Earlier preclinical evidence for complement activation un-
derlying the infusion rate-dependence of HSRs was provided
in a porcine model of liposome-induced CARPA, wherein the
speed of liposome infusion showed remarkable correlation with
the rise of pulmonary arterial pressure (Szebeni et al., 2000),
which, in turn, was shown to arise as a consequence of comple-
ment activation-related anaphylatoxin production (Szebeni
et al., 1999, 2000). These facts taken together suggest that the
slow-infusion-based LRPs may be effective when complement
activation is a major pathogenic factor for HSRs.
Among further in vivo evidence for CARPA as a common
underlyingmechanism of HSRs, it has been shown that HSRs,
not only to liposomes, but also to polymers, dendrimers, car-
bon nanotubes and a wide range of other nanoparticles, are
also complement activation-related, and the symptoms are
similar and closely mimic human HSRs and anaphylaxis
(Szebeni, 2012). Studies on this phenomenon have
established that the reactogenic complement-activating
nanoparticles are usually highly charged and/or coated by re-
petitive surface projections from polymers, carbohydrate,
peptides, etc., that bind antigen or pattern recognition mole-
cules (IgM, IgG, C1q, mannose binding lectin (MBL) and
ﬁcolin). Crystalline surfaces (shown for silica and paclitaxel;
Szebeni et al., 2003) as well as 71% cholesterol-containing
liposomes, in which the cholesterol is partially crystallized
(Szebeni et al., 2001; Baranyi et al., 2003), are also effective
complement activators and inducers of HSR. Because all
existing IV-iron medicines consist of crystalline iron
oxide/hydroxide nanoparticle cores (up to 10–20 nm) and a
carbohydrate shell (from mannitol, dextran, gluconate su-
crose, carboxymaltose, isomaltoside, etc.) (Fütterer et al.,
2013), preconditions for complement activation via crystal
and carbohydrate recognition molecules exist with all IV-iron
medicines. In addition, some of the iron–carbohydrate com-
plexes can also agglomerate to form large clusters (up to
200 nm) (Fütterer et al., 2013), providing further surface for
complement activation.
Although we are not aware of studies showing comple-
ment activation by reactogenic IV-iron medicines, a recent
study provided evidence for such activation by dextran-
coated superparamagnetic iron oxide (SPIO) nanoparticles
used as a magnetic resonance imaging (MRI) contrast agent
(Banda et al., 2014). The latter study also investigated the
mechanism of complement activation in human and mouse
serum and found evidence for prominent involvement of
the lectin pathway (via MBL or L-ﬁcolin) and triggering of al-
ternative ampliﬁcation loop (Banda et al., 2014). Because the
SPIO nanoparticles can also cause major HSRs in patients,
and because the basic structure of all IV-iron medicines
and iron-oxide core/dextran shell containing MRI contrast
agents are very similar, it is highly likely that complement
Table 4
Reactive treatment options to manage HSRs to intravenous drugs including IV-iron (Rampton et al., 2014)
Symptoms Treatment options
Mild HSRs Itching, urticaria, ﬂushing, sensation of heat,
slight chest tightness, hypertension and back/
joint pains
Stop infusion temporarily and watch
symptoms and signs. If symptoms improve
the infusion can be restarted cautiously.
Moderate HSRs As in mild reaction + cough, chest tightness,
nausea, shortness of breath, tachycardia
and hypotension
Stop infusion and consider IV-ﬂuids and
IV-corticosteroids.
Severe HSRs = life-
threatening anaphylaxis
As in moderate + sudden onset and rapid
aggravation of symptoms + wheezing, stridor,
periorbital oedema, cyanosis, loss of
consciousness and cardiac/respiratory arrest
As for moderate HSRs + IM or IV adrenaline
(epinephrine) + consider β2-adrenoceptor
agonist inhaler, O2 by facemask, act
according to local standard anaphylaxis
guidelines.
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activation by IV-iron can occur in man via the same or
similar mechanism and may cause or contribute to the rare
occurrence of non-IgE-mediated HSRs.
These facts and considerations, taken together with the
reported success of slow infusion protocols in preventing
life-threatening reactions to IV-iron (Altman and Petersen,
1988; Monaghan et al., 1994; Hickman et al., 2000) suggest
that CARPA, the proposed mechanism of very frequent lipo-
some and antibody and taxane reactions, also represents the
most likely mechanism underlying the reactions to IV-iron.
The difference in prevalence might arise from differences in
the extent of complement activation and/or the general sen-
sitivity of patients for activation by these agents.
As for the chain of events leading from complement acti-
vation to HSRs, the anaphylatoxins C3a and C5a bind tomast
cells (and basophil leukocytes and macrophages) via speciﬁc
receptors on these cells and trigger the release of a great num-
ber of vasoactive mediators that cause the symptoms of HSRs
listed in Figure 1.
Figure 2 illustrates the anaphylatoxin concept of HSRs
caused by drug particles. In the rare patients developing these
reactions, iron, or other nanoparticle-based drugs, activate
the complement system (upper red arrow) that leads to the
formation of anaphylatoxins. Their blood level is determined
by generation via this activation process, and by consump-
tion, due partly to cellular uptake and partly to metabolism
by carboxypeptidases (green) (Campbell et al., 2002). The
level in blood determines whether or not anaphylatoxins
trigger mast cells for release reaction (lower red arrow). A
scheme of complement activation (left insert) and the main
vasoactive mediators released frommast cells are also shown.
Figure 2 may also explain why a low speed of infusion is
an effective way of preventing HSRs to all reactogenic drugs,
including IV-iron; it is hypothesized that the changes in
anaphylatoxin equilibrium are fast, so that a slow infusion
may keep the concentration of anaphylatoxins below the
HSR threshold of allergy-mediating cells (mast cells, baso-
phils and certain macrophages), while massive and rapid
exposure to a complement activator may tip the balance
towards anaphylatoxin build-up, and hence exceed the HSR
threshold (Figure 2).
Conclusions and outlook
This paper represents an extension of an earlier review of IV-iron
reactions, which focused on risk minimization and manage-
ment (Rampton et al., 2014). Here we compare the various
features of IV-iron and other IV drug-induced HSRs in order to
uncover possible clues regarding their mechanism and how to
improve therapy. Our particular scientiﬁc question was as fol-
lows: ‘What is the available direct or indirect evidence for shared
molecular mechanisms that have implications for the preven-
tion and treatment of HSRs, in general, and of IV-iron reactions,
in particular?’ The comparison focused on the symptoms, prev-
alence, kinetics, duration, tolerance andmolecularmechanisms
of HSRs and came to the conclusion that complement activa-
tion and subsequent anaphylatoxin production may be a com-
mon underlying cause for many HSRs to IV drugs, including
IV-iron. The review addresses the difﬁculties of nomenclature
and clinical studies in allergy research and points out that the
treatment of IV-iron reactions is based on empirical traditions
rather than clinical research. It is also emphasized that as further
evidence becomes available, the recent EMA guidance on risk
minimization for very rare IV-iron reactions should be extended
or revised with recommendations for speciﬁc and effective new
interventions against HSRs to iron, for example by using slow
infusion-based LRPs that are known to attenuate CARPA. It is
clear that future research needs for the prevention andmanage-
ment of immune-mediated drug hypersensitivity reactions
(Adkinson et al., 2002), and the anaphylatoxin concept may
spur many more complement-focused desensitization or treat-
ment ideas.
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